問卷

TPIDB > Search Result

Search Result

篩選

List

61Cases

2023-08-01 - 2029-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2023-07-01 - 2031-11-06

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2023-06-01 - 2028-11-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2020-07-01 - 2026-01-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-09-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-03-01 - 2030-07-16

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-07-01 - 2029-09-19

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-04-08 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2020-01-31 - 2023-10-03

Phase II/III

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  • Test Drug

    GSK3359609

Participate Sites
7Sites

Recruiting7Sites

2021-05-20 - 2023-05-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites